Interleukin-2 inducible T-cell kinase (ITK) (ITK)

Interleukin-2 inducible T-cell kinase (ITK) is a non-receptor tyrosine kinase of the TEC family that serves as a critical signaling node in T-lymphocytes. Upon T-cell receptor (TCR) stimulation, ITK is recruited to the plasma membrane and activated by Lck, where it subsequently phosphorylates phospholipase C-gamma 1 (PLC-gamma1) [1]. This enzymatic activity triggers calcium flux and the activation of downstream transcription factors, most notably the nuclear factor of activated T-cells (NFAT), which drives the expression of key cytokines such as IL-2 and IL-13 [2]. ITK is particularly vital for the development and function of Th2 cells, making it a strategic target for treating allergic and inflammatory diseases like asthma and atopic dermatitis [3]. Additionally, its role in T-cell proliferation and survival has led to its investigation as a target in T-cell malignancies, such as T-cell lymphoma [4]. Drugs targeting ITK, such as soquelitinib, aim to selectively modulate these effector pathways to suppress pathological immune responses without the broad immunosuppression associated with calcineurin inhibitors [5]. The provided name 'Activated T-lymphocyte effector pathways controlling IL-2 and IL-13 production' is a descriptive phrase for the biological process mediated by ITK rather than a canonical molecular target name.

Other names

IL-2 inducible T-cell kinaseEMTLYKPSCTK1Tyrosine-protein kinase ITK/TSKT-cell-specific tyrosine kinaseActivated T-lymphocyte effector pathways controlling IL-2 and IL-13 production

Inhibition of ITK kinase activity, which prevents the phosphorylation of PLC-gamma1 and subsequent calcium-dependent activation of NFAT, thereby blocking the transcription of IL-2 and IL-13 genes.